Literature DB >> 1674493

A retrospective analysis of breast cancer based on outcome differences.

S R Wolman1, H D Feiner, R A Schinella, P Gimotty, H Ownby, T Maloney, P J Dawson.   

Abstract

We reviewed tumors from two groups of patients with breast cancer, distinguished by differences in outcome. One group (85 cases) survived more than 8.5 years without tumor recurrence; the other 85 cases had recurrent disease within 2 years. Histologic and immunocytochemical studies on all cases were performed without patient identifiers and prior to review of clinical prognostic factors. As expected, lymph node and estrogen receptor status differed substantially between the groups, but menopausal status and family history for breast cancer did not. We noted that 27% of node-negative patients died within 5 years, and nine patients with four or more tumor-containing nodes were symptom-free for over 8.5 years. Histologic grade (degree of tubule formation) and nuclear grade (including mitotic rate) differed significantly between the groups, as did vascular invasion, including both lymphatics and blood vessels. Prognostic value attached to tumor border only when fat was invaded without fibroblastic or inflammatory response (P = .012). Subgrouping cases of infiltrating ductal carcinoma (not otherwise specified) was prognostically informative in the B subgroup, 69% of whom were in the rapidly recurrent tumor group. Immunocytochemical staining for c-erbB-2 was positive in 19.3% of cases, but was equally distributed between the two outcome groups. We conclude that traditional histologic parameters are highly informative, and that c-erbB-2 studies do not increase the value of histologic diagnosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674493     DOI: 10.1016/0046-8177(91)90134-b

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Bilateral breast cancer: one disease or two?

Authors:  P J Dawson; T Maloney; P Gimotty; P Juneau; H Ownby; S R Wolman
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

2.  INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes.

Authors:  R J Pauley; P A Gimotty; T J Paine; P J Dawson; S R Wolman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  High DNA content and prognosis in lymph node positive breast cancer. A case control study by the University of Leiden and ECOG. (Eastern Cooperative Oncology Group).

Authors:  K W Gilchrist; R Gray; A M van Driel-Kulker; W E Mesker; J J Ploem-Zaaijer; J S Ploem; S G Taylor; D C Tormey
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

4.  Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice.

Authors:  R R Mehta; J M Graves; M A Warso; T K Das Gupta
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.